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In 2013, the global tuberculosis (TB) incidence was 126 cases per 100,000 population, corresponding to 9.0 million incident cases worldwide, of which 480,000 were multidrug-resistant TB (MDR-TB) ([@B1]). The same year, TB caused about 1.5 million deaths worldwide. By the end of 2012, 92 countries reported extensively drug-resistant TB (XDR-TB) cases to WHO, and 100 countries reported it in 2013. An estimated 9.0% of MDR-TB cases were XDR-TB ([@B1]). The continued increase and spread of XDR-TB cases is becoming a serious threat to public health worldwide, as well as to the long-term elimination target set for 2050.

Studies in South America have revealed that the Beijing family accounts for 1% to 2% of the clinical isolates ([@B2], [@B3]). However, occasionally rates as high as 5% or 10% have been reported in Peru and Colombia, the latter being in the harbor city of Buenaventura ([@B4], [@B5]). To better understand the molecular mechanisms involved in the extensive drug resistance of *M. tuberculosis* strains from the Beijing family, we sequenced the whole genome of a sputum clinical isolate from Buenaventura, Colombia.

24-locus MIRU VNTR genotyping was used to confirm the assignment of isolate TBR-103 to the *M. tuberculosis* Beijing lineage ([@B6]). Phenotypic susceptibility tests were performed using the Bactec MGIT 960 method. It was determined that TBR-103 is resistant to isoniazid, rifampin, ethambutol, streptomycin, ofloxacin, moxifloxacin, and amikacin, and therefore is classified as XDR-TB. Genomic DNA was obtained from isolate TBR-103 by the CTAB method ([@B7]). Samples were treated with RNase prior to paired-end library construction with an average target insert size of 800 bp. Whole-genome sequencing was performed at the J. Craig Venter Institute (JCVI) in Rockville, Maryland, USA, on a MiSeq Illumina platform with 250-bp reads. The genomic DNA was sequenced to about 70× coverage. The draft whole-genome sequence is composed of 4,298,162 bp and 64.94% GC with an *N*~50~ contig length of 60,737 bp. The Celera Assembler was used to perform a *de novo* assembly. JCVI's in-house pipeline, which uses multiple ranked sources of evidence, including the TIGRFAMs and Pfam protein family databases, provided structural and functional annotation. The assembly contained 4,359 protein-coding genes, along with 45 tRNAs. Mutations associated with resistance to rifampin (S450L in *rpoB*), isoniazid (S315T and R463L in *katG*), ethambutol (M306V in *embB*), and streptomycin (K43R in *rpsL*) were encountered. Also, several SNPs associated with resistance to aminoglycosides were found, such as A1401G in the *rrs* gene, as well as the deletions 805A and 808C in the *eis* gene. No mutation associated with resistance to fluoroquinolones was detected in *gyrA* or *gyrB* genes.

This is the second whole-genome sequencing report of a Beijing XDR-TB isolate circulating in Colombia ([@B8]). This will provide a foundation for comparative genomic analysis with XDR-TB genomes circulating in the Americas, as well as in other regions of the world ([@B9][@B10][@B13]).
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This genome project has been deposited at DDBJ/EMBL/GenBank under the accession number [JRJT00000000](JRJT00000000). The version described in this paper is the first version, JRJT01000000.
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